Skip to main content
Premium Trial:

Request an Annual Quote

Schering Expands Target Validation Collaboration with Atugen to Include RNAi

NEW YORK, June 17 - Schering has extended a collaboration with Atugen of Berlin to validate drug targets associated with cancer using Atugen's KnockDown technology.

 

The two companies have been collaborating for six years so far. The new agreement adds two more years to the partnership, and has been expanded to include Atugen's RNA interference technology. Atugen will develop its GeneBloc antisense molecules and/or siRNA molecules that are designed to inhibit expression of drug target candidates selected by Schering. Atugen will analyze the effects of the knockdown to validate gene function and disease association.

 

Under the terms of the new agreement, Atugen will receive annual licensing fees, research funding, and milestone payments.

 

Atugen will be working with Schering's research scientists in Germany and its Berlex Biosciences subsidiary in California.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more